Werbung
Deutsche Märkte öffnen in 4 Stunden 20 Minuten
  • Nikkei 225

    38.458,27
    +102,21 (+0,27%)
     
  • Dow Jones 30

    39.558,11
    +126,60 (+0,32%)
     
  • Bitcoin EUR

    57.052,34
    -743,71 (-1,29%)
     
  • CMC Crypto 200

    1.270,61
    -20,78 (-1,61%)
     
  • Nasdaq Compositive

    16.511,18
    +122,94 (+0,75%)
     
  • S&P 500

    5.246,68
    +25,26 (+0,48%)
     

Conference Call on Interim Report

XVIVO Perfusion AB

GOTHENBURG, SE / ACCESSWIRE / October 21, 2022 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report January-September 2022. The presentation will be held in English.

Time: Thursday, October 27 at 2.00 p.m. CET

To join the conference call from your computer, use the following link:
https://onlinexperiences.com/Launch/QReg/ShowUUID=DC9EC0A8-A38E-4EAD-A1E0-7C962D4BB5FD

Phone numbers to the conference:
Sweden: +46 856642651 PIN: 82398789#
UK: +44 3333000804 PIN: 82398789#
US: +1 6319131422 PIN: 82398789#
Conference name: XVIVO Interim Report Q3 2022

Participants from XVIVO:
Christoffer Rosenblad, acting CEO
Kristoffer Nordström, CFO

The press release for XVIVO's interim report January-September 2022 will be released on October 27, 2022 at 7:30 a.m. CET.

Before the conference call, slides will be available at the company web page, https://www.xvivoperfusion.com/corporate/financial-presentations/earnings-calls/

October 21, 2022
Gothenburg
XVIVO Perfusion AB (publ)

WERBUNG

For further information, please contact:

Christoffer Rosenblad, Acting CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

Attachments

Conference call on Interim Report

SOURCE: XVIVO Perfusion AB



View source version on accesswire.com:
https://www.accesswire.com/721546/Conference-Call-on-Interim-Report